Current status and future opportunities for incorporation of dissolution data in pbpk modeling for pharmaceutical development and regulatory applications: orbito consortium commentary.

In vitro dissolution experiments are used to qualitatively assess the impact of formulation composition and process changes on the drug dosage form performance. However, the use of dissolution data to quantitatively predict changes in the absorption profile remains limited. Physiologically-based Pharmacokinetic(s) (PBPK) models facilitate incorporation of in vitro dissolution experiments into mechanistic oral absorption models to predict in vivo oral formulation performance, and verify if the drug product dissolution method is biopredictive or clinically relevant. Nevertheless, a standardized approach for using dissolution data within PBPK models does not yet exist and the introduction of dissolution data in PBPK relies on a case by case approach which accommodates from differences in release mechanism and limitations to drug absorption. As part of the Innovative Medicines Initiative (IMI) Oral Biopharmaceutics Tools (OrBiTo) project a cross-work package was set up to gather a realistic understanding of various approaches used and their areas of applications. This paper presents the approaches shared by academic and industrial scientists through the OrBiTo project to integrate dissolution data within PBPK software to improve the prediction accuracy of oral formulations in vivo. Some general recommendations regarding current use and future improvements are also provided.

[1]  Martin Bergstrand,et al.  PBPK models for the prediction of in vivo performance of oral dosage forms. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  Nikunjkumar Patel,et al.  Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process , 2016, The AAPS Journal.

[3]  M. Karlsson,et al.  The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop , 2013, CPT: pharmacometrics & systems pharmacology.

[4]  Lynne S Taylor,et al.  Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  Filippos Kesisoglou,et al.  PBPK Absorption Modeling: Establishing the In Vitro–In Vivo Link—Industry Perspective , 2019, The AAPS Journal.

[6]  A. Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology , 2012, Clinical pharmacology and therapeutics.

[7]  Filippos Kesisoglou,et al.  Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  L. Chinn,et al.  Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria. , 2017, Molecular pharmaceutics.

[9]  G. Amidon,et al.  In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen , 2012, Biopharmaceutics & drug disposition.

[10]  Steven C. Sutton,et al.  Role of Physiological Intestinal Water in Oral Absorption , 2009, The AAPS Journal.

[11]  Anette Müllertz,et al.  In vitro models for the prediction of in vivo performance of oral dosage forms. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Arzu Selen,et al.  Prediction of in‐vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in‐vitro–in‐silico–in‐vivo approach , 2015, The Journal of pharmacy and pharmacology.

[13]  W. S. Koski,et al.  Correlation between the growth inhibitory effects, partition coefficients and teratogenic effects of lipophilic acids. , 1979, Teratology.

[14]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[15]  C. Regårdh,et al.  Felodipine kinetics in healthy men , 1985, Clinical pharmacology and therapeutics.

[16]  H. Wen,et al.  Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products , 2017, The AAPS Journal.

[17]  J. Parojčić,et al.  In vitro--in silico--in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: nifedipine osmotic release tablets case study. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  R. Ziff,et al.  Mass Transport Analysis of Bicarbonate Buffer: Effect of the CO2-H2CO3 Hydration-Dehydration Kinetics in the Fluid Boundary Layer and the Apparent Effective p Ka Controlling Dissolution of Acids and Bases. , 2019, Molecular pharmaceutics.

[19]  N. Patel,et al.  Integrating drug- and formulation-related properties with gastrointestinal tract variability using a product-specific particle size approach: case example ibuprofen. , 2019, Journal of pharmaceutical sciences.

[20]  Mark McAllister,et al.  Dynamic dissolution: a step closer to predictive dissolution testing? , 2010, Molecular pharmaceutics.

[21]  Martin Culen,et al.  Designing a dynamic dissolution method: a review of instrumental options and corresponding physiology of stomach and small intestine. , 2013, Journal of pharmaceutical sciences.

[22]  W. Weitschies,et al.  Simulating the postprandial stomach: physiological considerations for dissolution and release testing. , 2013, Molecular pharmaceutics.

[23]  S. Yamashita,et al.  Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation , 2008, Pharmaceutical Research.

[24]  Filippos Kesisoglou,et al.  Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  Gavin K Reynolds,et al.  Mechanistic insights into the dissolution of spray-dried amorphous solid dispersions. , 2012, Journal of pharmaceutical sciences.

[26]  N. Patel,et al.  Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug. , 2017, Molecular pharmaceutics.

[27]  J. Lippert,et al.  Integration of dissolution into physiologically‐based pharmacokinetic models III: PK‐Sim® , 2012, The Journal of pharmacy and pharmacology.

[28]  Amitava Mitra,et al.  Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link—a Workshop Summary Report , 2019, The AAPS Journal.

[29]  Patrick Augustijns,et al.  Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study. , 2017, Molecular pharmaceutics.

[30]  Hoo-Kyun Choi,et al.  Preparation of a solid dispersion of felodipine using a solvent wetting method. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  M. Bolger,et al.  Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives , 2020, Pharmaceutical Research.

[32]  G. Nyberg,et al.  Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. , 1987, Biopharmaceutics & drug disposition.

[33]  Anna Eidelman,et al.  Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets. , 2016, Molecular pharmaceutics.

[34]  J. Dressman,et al.  Upper Gastrointestinal (GI) pH in Young, Healthy Men and Women , 1990, Pharmaceutical Research.

[35]  P. Galle,et al.  A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[36]  Jennifer Dressman,et al.  Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in‐vivo performance of solid oral dosage forms , 2013, The Journal of pharmacy and pharmacology.

[37]  P. Galle,et al.  In vitro prediction of in vivo absorption of ibuprofen from suspensions through rational choice of dissolution conditions. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[38]  Xavier Pepin,et al.  Mechanistic investigation of the negative food effect of modified release zolpidem , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  M. Nijsen,et al.  Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story. , 2018, Journal of pharmaceutical sciences.

[40]  N. Hosten,et al.  Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging , 2005, Alimentary pharmacology & therapeutics.

[41]  Ping Zhao,et al.  Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status , 2017, CPT: pharmacometrics & systems pharmacology.

[42]  C. Krejsa,et al.  Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  P. Chalus,et al.  Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing , 2017, The AAPS Journal.

[44]  Anette Müllertz,et al.  In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[45]  Katie L. Cavanagh,et al.  Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions. , 2018, Molecular pharmaceutics.

[46]  B. Edgar,et al.  Bioavailability from felodipine extended-release tablets with different dissolution properties , 1990 .

[47]  B. Abrahamsson,et al.  Evaluation of Solubilizers in the Drug Release Testing of Hydrophilic Matrix Extended-Release Tablets of Felodipine , 1994, Pharmaceutical Research.

[48]  Wei Xu,et al.  Advances and challenges in PBPK modeling--Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[49]  H. Jones,et al.  Application of Physiologically Based Pharmacokinetic Modeling to Understanding the Clinical Pharmacokinetics of UK-369,003 , 2011, Drug Metabolism and Disposition.

[50]  R. Löbenberg,et al.  The Irrelevance of In Vitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping. , 2019, Journal of pharmaceutical sciences.

[51]  Thierry Lavé,et al.  Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.

[52]  J. Dressman,et al.  Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[53]  N Parrott,et al.  Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective , 2015, Clinical pharmacology and therapeutics.

[54]  Filippos Kesisoglou,et al.  Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies. , 2016, Journal of pharmaceutical sciences.

[55]  E Luzon,et al.  Physiologically based pharmacokinetic modeling in regulatory decision‐making at the European Medicines Agency , 2017, Clinical pharmacology and therapeutics.

[56]  F. Kesisoglou,et al.  Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm , 2015, The AAPS Journal.

[57]  Filippos Kesisoglou,et al.  Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report , 2018, The AAPS Journal.

[58]  Bertil Abrahamsson,et al.  Can the USP paddle method be used to represent in‐vivo hydrodynamics? , 2003, The Journal of pharmacy and pharmacology.

[59]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[60]  John D. Davis,et al.  Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics , 2017, CPT: pharmacometrics & systems pharmacology.

[61]  H Lennernäs,et al.  In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context. , 2017, Molecular pharmaceutics.

[62]  N. Patel,et al.  Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation‐dependent effect of achlorhydria , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[63]  R Lionberger,et al.  Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop , 2017, CPT: pharmacometrics & systems pharmacology.

[64]  C. Regårdh,et al.  Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[65]  Filippos Kesisoglou,et al.  Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report , 2018, The AAPS Journal.

[66]  Gregory K. Webster,et al.  In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities , 2019, AAPS PharmSciTech.

[67]  M. Bolger,et al.  Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus™. , 2019, Journal of pharmaceutical sciences.

[68]  M. Jamei,et al.  Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models. , 2019, Journal of pharmaceutical sciences.

[69]  Kiyohiko Sugano,et al.  Oral Absorption of Poorly Water-Soluble Drugs: Computer Simulation of Fraction Absorbed in Humans from a Miniscale Dissolution Test , 2006, Pharmaceutical Research.

[70]  Kerby Shedden,et al.  A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP , 2020, Pharmaceutics.

[71]  Alexander Blanazs,et al.  Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[72]  M Jamei,et al.  ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans , 2013, Clinical pharmacology and therapeutics.

[73]  F. Kesisoglou,et al.  Physiologically Based Absorption Modeling for Amorphous Solid Dispersion Formulations. , 2016, Molecular pharmaceutics.

[74]  B. Edgar,et al.  Pharmacokinetics and hemodynamic and diuretic/natriuretic effects of felodipine administered as an extended-release tablet , 1990, Cardiovascular Drugs and Therapy.

[75]  Liang Zhao,et al.  Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended‐Release Case Study , 2019, Journal of clinical pharmacology.

[76]  Amitava Mitra,et al.  In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole. , 2017, Molecular pharmaceutics.

[77]  Filippos Kesisoglou,et al.  Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies. , 2019, Journal of pharmaceutical sciences.

[78]  Andreas M. Abend,et al.  Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and Commercialization. , 2018, Journal of pharmaceutical sciences.